Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
1st Lucentis Biosimilar, 3rd Humira Follow-On Get Japan Listing
The first biosimilar of Novartis’ vascular endothelial growth factor (VEGF) inhibitor Lucentis (ranibizumab) in Japan, developed by Senju Pharmaceutical, will join the NHI price list on November 25, according to the government’s official gazette issued on November 24. Ranibizumab BS…
To read the full story
Related Article
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Lucentis Biosimilar Now Approved for Diabetic Macular Edema
January 16, 2023
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
REGULATORY
- MHLW Pharma Chief Eyes Wider Use of English Drug Filings to Stem Drug Loss
September 25, 2026
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…